Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness

Stock Information for Cingulate Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cingulate Inc.

Shane Schaffer, Cingulate Chairman & CEO to Present "SMART Launch" Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
Cingulate Receives Complete Response Letter from FDA for CTx-1301
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.